The high expression of NAP1L1 has existed in the heap of human neoplasms covering nasopharyngeal carcinoma (Liu S. et al., 2021), lung adenocarcinoma (Nagashio et al., 2020), glioblastoma (Zottel et al., 2020), colon cancer (Aydin et al., 2020), colorectal cancer (Queiroz et al., 2020), breast cancer (Liu S. et al., 2021), small-intestinal carcinoid (Kidd et al., 2006), and pancreatic neuroendocrine neoplasm (Schimmack et al., 2014). Here, NAP1L1 is linked to glioblastoma.